Evidence map›Paper›PMID 41373861›Full record

Observational studyInternational journal of molecular sciences2025

Diagnostic and Prognostic Potential of CXCL9 and CXCL10 Chemokines in Alcohol-Associated Liver Disease.

Agnieszka Szczerbinska, Jacek Rolinski, Agata Surdacka, Halina Cichoz-Lach

Abstract readObservational Study
In one paragraph

Observational study in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Agnieszka SzczerbinskaDoctoral School, Medical University of Lublin, 20-950 Lublin, Poland.ORCID 0009-0000-5869-9043
Jacek RolinskiDepartment of Clinical Immunology, Medical University of Lublin, 20-950 Lublin, Poland.ORCID 0000-0003-4841-6120
Agata SurdackaDepartment of Clinical Immunology, Medical University of Lublin, 20-950 Lublin, Poland.ORCID 0000-0002-0307-7535
Halina Cichoz-LachDepartment of Gastroenterology and Hepatology with Endoscopy Unit, Medical University of Lublin, 20-090 Lublin, Poland.ORCID 0000-0002-7337-835X

Funding

Medical University of Lublin DS 369, DS 360/2022-2024
6 · The paper itself

Abstract

Alcohol-associated liver disease (ALD) is the leading cause of liver-related mortality. In ALD, excessive inflammatory response may induce a massive loss of hepatocytes and lead to irreversible liver damage with progressive fibrosis. Chemokines stimulate the migration of immune cells to the site of inflammation and contribute to the inflammatory cascade that may result in organ failure. We aimed to investigate blood concentrations of CXCL9/MIG, CXCL10/IP-10, and CXCL16 chemokines and their diagnostic and prognostic significance in patients with ALD. In a prospective observational study, 88 individuals were recruited, including 63 patients with ALD (44 men and 19 women, aged 48.49 ± 10.88) and 25 healthy control volunteers matched for age, sex, and ethnicity. In blood samples, concentrations of CXCL9/MIG, CXCL10/IP-10, and CXCL16 were measured using immunoenzymatic ELISAs. Correlations were examined between CXCL levels and (a) traditional inflammatory markers (C-reactive protein, white blood cell count, neutrophil count, lymphocyte count, and neutrophil-to-lymphocyte ratio-NLR) and (b) liver dysfunction severity scores: Child-Turcotte-Pugh (CTP), MELD-NA, MELD 3.0, and modified Maddrey's discriminant function (mDF). Patients' survival within 30 days of hospital admission was recorded for analysis. CXCL capabilities in predicting the severity of liver dysfunction and ALD outcome were validated. ALD patients showed significant systemic upregulation of all studied chemokines compared to the control group. Patients with advanced liver disease, classified as MELD-Na ≥ 20, MELD3.0 > 19, and CTP class C, as well as poor short-term outcomes, presented with significantly higher CXCL9 and CXCL10 levels compared to their counterparts. ALD non-survivors had significantly higher concentrations of all studied CXCLs in comparison to controls. Positive correlations between CXCL16 and CRP, leukocytosis, neutrophils, and NLR were confirmed (0.67; 0.46; 0.48; 0.54, respectively). Although none of the chemokines correlated with ALT activity, CXCL9, CXCL10, and CXCL16 showed positive correlations with bilirubin and alkaline phosphatase and inverse correlations with albumin levels. Our findings revealed the diagnostic and prognostic value of the studied CXCLs in ALD. In particular, CXCL9 and CXCL10 may have potential for discrimination of severe liver dysfunction and poor short-term prognosis. Further multicenter studies are required to confirm our results.

Indexed as

Chemokine CXCL10Chemokine CXCL9Liver Diseases, AlcoholicAdultBiomarkersCase-Control StudiesChemokine CXCL16FemaleHumansMaleMiddle AgedPrognosisProspective StudiesROC CurveBiomarkersChemokine CXCL10Chemokine CXCL16Chemokine CXCL9CXCL10 protein, humanCXCL9 protein, humanalcohol-associated liver diseaseCXCL10/IP-10CXCL16CXCL9/MIGC-X-C motif chemokines

Identifiers

PMID41373861
PMCPMC12691941

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.